Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 908 | 981 | 1151 | 1503 | 2004 | 3751 |
Fund Return | -9.17% | -1.9% | 15.1% | 14.56% | 14.92% | 14.13% |
Place in category | 228 | 132 | 13 | 9 | 13 | 26 |
% in Category | 38 | 27 | 4 | 3 | 2 | 10 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AB FCP IAmericanGrwthPf C EUR H Acc | 7.96B | 17.81 | 4.80 | 11.94 | ||
AB FCP IAmericanGrwthPf A EUR H Acc | 7.96B | 18.20 | 5.28 | 12.45 | ||
AB FCP IAmericanGrwthPf I EUR H Acc | 7.96B | 18.91 | 6.13 | 13.33 | ||
Japan Strategic Value Portfolio S1e | 2.94B | 17.43 | 2.82 | 8.48 | ||
AB FCP IJapStratValuePrtfloI AccEUR | 2.94B | 3.87 | 9.29 | 10.31 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
World Healthscience Fund C2e | 396.46M | 11.91 | 3.74 | 7.53 | ||
World Healthscience Fund D2e | 1.37B | 13.59 | 5.84 | 9.70 | ||
World Healthscience Fund A2e | 6.96B | 12.96 | 5.05 | 8.88 | ||
World Healthscience Fund E2e | 2.26B | 12.54 | 4.53 | 8.34 | ||
LU1960219571 | 1.52B | 13.82 | 6.09 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 10.37 | 557.77 | -1.72% | |
Roche Holding Participation | CH0012032048 | 7.98 | 272.30 | -0.29% | |
Novo Nordisk A/S Class B | DK0060534915 | 5.99 | - | - | |
Amgen | US0311621009 | 5.68 | 316.91 | -0.72% | |
Vertex | US92532F1003 | 5.20 | 472.80 | +0.36% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review